Reslizumab is a monoclonal antibody that specifically targets interleukin-5 (IL-5), a cytokine involved in the growth, differentiation, recruitment, and activation of eosinophils, which are white blood cells that play a key role in allergic responses and asthma. It is primarily used in the treatment of severe asthma with an eosinophilic phenotype. Reslizumab is administered via intravenous infusion and is characterized by its ability to reduce eosinophil levels in the blood, thereby decreasing asthma exacerbations and improving lung function. The molecular structure of Reslizumab is that of a humanized IgG4 antibody, which enhances its stability and reduces immunogenicity. Common side effects may include headache, oropharyngeal pain, and potential allergic reactions. As with other biologics, careful monitoring is essential during treatment to manage any adverse effects and assess therapeutic efficacy. Overall, Reslizumab represents a targeted therapeutic approach in managing severe asthma, particularly in patients with elevated eosinophil counts.

Reslizumab

241473-69-8: Immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal SCH 55700 γ4-chain), disulfide with human-rat monoclonal SCH 55700 light chain, dimer, Reslizumab, Sch 55700, DCP 835, Cinquil

Anti-IL-5 humanized monoclonal antibody; used in asthma treatment

Reslizumab (Sch 55700) is a humanized immunoglobulin G (IgG) 4 κ monoclonal antibody, thereby reducing eosinophil production and survival.

CAS 241473-69-8: Reslizumab

Reslizumab

Ref: 3D-CLA1210

Reslizumab

Ref: TM-T12706